Sapphire Star Partners Lp Lowers stake in ABIOMED (ABMD)

ABIOMED (ABMD) : Sapphire Star Partners Lp reduced its stake in ABIOMED by 21.06% during the most recent quarter end. The investment management company now holds a total of 3,051 shares of ABIOMED which is valued at $335,641 after selling 814 shares in ABIOMED , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.ABIOMED makes up approximately 0.41% of Sapphire Star Partners Lp’s portfolio.

Other Hedge Funds, Including , Jnba Financial Advisors added ABMD to its portfolio by purchasing 6,491 company shares during the most recent quarter which is valued at $714,075. ABIOMED makes up approx 0.11% of Jnba Financial Advisors’s portfolio.New York State Teachers Retirement System reduced its stake in ABMD by selling 1,800 shares or 2.19% in the most recent quarter. The Hedge Fund company now holds 80,500 shares of ABMD which is valued at $8,633,625. ABIOMED makes up approx 0.02% of New York State Teachers Retirement System’s portfolio.Comerica Bank boosted its stake in ABMD in the latest quarter, The investment management firm added 810 additional shares and now holds a total of 27,995 shares of ABIOMED which is valued at $3,002,464. ABIOMED makes up approx 0.03% of Comerica Bank’s portfolio. Hwg Holdings Lp added ABMD to its portfolio by purchasing 38,248 company shares during the most recent quarter which is valued at $4,055,053. ABIOMED makes up approx 4.49% of Hwg Holdings Lp’s portfolio. Geneva Advisors added ABMD to its portfolio by purchasing 2,213 company shares during the most recent quarter which is valued at $234,622.

ABIOMED closed down -0.19 points or -0.17% at $113.41 with 8,17,781 shares getting traded on Monday. Post opening the session at $113.51, the shares hit an intraday low of $113.04 and an intraday high of $114.7 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, ABIOMED reported $0.20 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on Oct 27, 2016. Analyst had a consensus of $0.25. The company had revenue of $103.00 million for the quarter, compared to analysts expectations of $103.12 million. The company’s revenue was up 35.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.17 EPS.

Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

ABIOMED - Is it time to Sell?

Top Brokerage Firms are advising their investors on ABIOMED. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.